Impact of Two Sofosbuvir-Containing Regimens on the Haematological and Biochemical Profiles of Egyptian Patients with Hepatitis C-related Compensated Cirrhosis

Abstract

Aim : This study aimed to evaluate the efficacy/safety of Sofosbuvir/Ribavirin and Sofosbuvir/Daclatasvir/Ribavirin in Egyptian cirrhotic HCV patients, and to demonstrate the effects on the haematological and biochemical profile. Patients and Methods: A Prospective study was done on 200 HCV cirrhotic patients. They were allocated into two Groups, Group 1: received Sofosbuvir (SOF) and Ribavirin (RBV) for 24 weeks, Group 2: received SOF, Daclatasvir (DAC) and RBV for 12 weeks. Results : Sustained virological response was achieved in 75 (75%) and 96 (96%) patients in Group 1, 2 respectively. The mean value of Hb and Platelet count decreased in a significant manner at treatment end in both Groups, and the percentage of drop was significantly higher in Group 1 in comparision to Group 2. The mean values of albumin, ALT, and AST decreased in a significant manner at treatment end in both Groups. There was a significant increase in total bilirubin mean value in both Groups at treatment end. The percent of the increase in the indirect bilurubin mean value was significantly higher in Group 2. There was improvement in FIB-4 score at treatment end in both Groups. This improvement was maintained to SVR 12 in both Groups. Conclusion: Cirrhotic patients received SOF, DAC and RBV for 12 weeks had a significantly higher SVR12 rate when compared to those received SOF and RBV for 24 weeks. In patients who achieved sustained virological response, there was improvement in liver function parameters, and FIB4 at the time of SVR12 in comparison to baseline values.